Tag: Prolong Pharmaceuticals
Prolong’s investigational therapy for acute ischaemic stroke receives US FDA breakthrough...
Prolong Pharmaceuticals has announced that its investigational therapy, pegylated carboxyhaemoglobin bovine (PP-007), has received a breakthrough therapy designation (BTD) from the US Food and...
Prolong Pharmaceuticals gains US FDA fast-track designation for novel stroke therapy
Prolong Pharmaceuticals has announced that its investigational therapy—PEGylated carboxyhemoglobin, bovine (PP-007)—has received a fast-track designation from the US Food and Drug Administration (FDA) for...
